Footnote. Link / Reference
a. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 2019;94(3):363-377
b. Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, and mastocytosis: a nationwide population-based study. Am J Hematol. 2016;91(11):1069-1075
c. Wimazal F, Geissler P, Shnawa P, et al. Severe life-threatening or disabiling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol. 2012;157(4):399-405.
d. van Anrooij B, Klun-Nelemans JC, Safy M, et al. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585-1593.
e. https://pubmed.ncbi.nlm.nih.gov/24565772/
f. https://jnccn.org/view/journals/jnccn/16/12/article-p1500.xml
g. https://rarediseases.info.nih.gov/diseases/8616/systemic-mastocytosis
h. https://ashpublications.org/blood/article/108/7/2366/22503
i. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-eparproduct- information_en.pdf
j. NCCN Systemic Mastocytosis. National Comprehensive Cancer Network. Accessed November 23, 2021 Version 3.2021 (https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=12496)
k. RYDAPT SmPC Novartis Europharm Ltd. Updated 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/rydapt-eparproduct- information_en.pdf
l. https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/symptoms-causes/syc-20352859
m. Pieri L, Bonadonna P, Elena C, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol. 2016;91(7):692-699.
n. Wimazal F, Geissler P, Shnawa P, et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol. 2012;157(4):399-405.
n/a. https://clinicaltrials.gov/ct2/show/NCT04996875?term=NCT04996875&draw=2&rank=1
o. https://rarediseases.info.nih.gov/diseases/8616/systemic-mastocytosis
p. https://ashpublications.org/blood/article/108/7/2366/22503
q. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-eparproduct- information_en.pdf
r. NCCN Systemic Mastocytosis. National Comprehensive Cancer Network. Accessed November 23, 2021 Version 3.2021 (https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=12496)
s. RYDAPT SmPC Novartis Europharm Ltd. Updated 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/rydapt-eparproduct- information_en.pdf
t. https://pubmed.ncbi.nlm.nih.gov/24565772/
u. https://jnccn.org/view/journals/jnccn/16/12/article-p1500.xml
https://www.cogentbio.com/privacy-policy/